Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (Nature Medicine, (2023), 29, 2, (422-429), 10.1038/s41591-022-02182-7)

Sham Mailankody; Jeffrey V. Matous; Saurabh Chhabra; Michaela Liedtke; Surbhi Sidana; Olalekan O. Oluwole; Shahbaz Malik; Rajneesh Nath; Faiz Anwer; Jose Carlos Cruz; Myo Htut; Erin E. Karski; Wade Lovelace; Myles Dillon; Eric Butz; Wendy Ying; Arun Balakumaran; Shaji K. Kumar

doi:10.1038/s41591-023-02306-7

Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (Nature Medicine, (2023), 29, 2, (422-429), 10.1038/s41591-022-02182-7)

Sham Mailankody, Jeffrey V. Matous, Saurabh Chhabra, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, Myo Htut, Erin E. Karski, Wade Lovelace, Myles Dillon, Eric Butz, Wendy Ying, Arun Balakumaran, Shaji K. Kumar

Hematology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Correction to: Nature Medicine. Published online 23 January 2023. In the version of this article initially published, the clinical trials registration number was missing from the Abstract and has now been amended in the HTML and PDF versions of the article.

Original language	English (US)
Pages (from-to)	3271
Number of pages	1
Journal	Nature Medicine
Volume	29
Issue number	12
DOIs	https://doi.org/10.1038/s41591-023-02306-7
State	Published - Dec 2023

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/s41591-023-02306-7

Fingerprint

Dive into the research topics of 'Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (Nature Medicine, (2023), 29, 2, (422-429), 10.1038/s41591-022-02182-7)'. Together they form a unique fingerprint.

Cite this

Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., Htut, M., Karski, E. E., Lovelace, W., Dillon, M., Butz, E., Ying, W., Balakumaran, A., & Kumar, S. K. (2023). Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (Nature Medicine, (2023), 29, 2, (422-429), 10.1038/s41591-022-02182-7). Nature Medicine, 29(12), 3271. https://doi.org/10.1038/s41591-023-02306-7

Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (Nature Medicine, (2023), 29, 2, (422-429), 10.1038/s41591-022-02182-7). / Mailankody, Sham; Matous, Jeffrey V.; Chhabra, Saurabh et al.
In: Nature Medicine, Vol. 29, No. 12, 12.2023, p. 3271.

Research output: Contribution to journal › Comment/debate › peer-review

Mailankody, S, Matous, JV, Chhabra, S, Liedtke, M, Sidana, S, Oluwole, OO, Malik, S, Nath, R, Anwer, F, Cruz, JC, Htut, M, Karski, EE, Lovelace, W, Dillon, M, Butz, E, Ying, W, Balakumaran, A & Kumar, SK 2023, 'Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (Nature Medicine, (2023), 29, 2, (422-429), 10.1038/s41591-022-02182-7)', Nature Medicine, vol. 29, no. 12, pp. 3271. https://doi.org/10.1038/s41591-023-02306-7

@article{436754da82c242b5beaa5c9ec066ad32,

title = "Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (Nature Medicine, (2023), 29, 2, (422-429), 10.1038/s41591-022-02182-7)",

abstract = "Correction to: Nature Medicine. Published online 23 January 2023. In the version of this article initially published, the clinical trials registration number was missing from the Abstract and has now been amended in the HTML and PDF versions of the article.",

author = "Sham Mailankody and Matous, {Jeffrey V.} and Saurabh Chhabra and Michaela Liedtke and Surbhi Sidana and Oluwole, {Olalekan O.} and Shahbaz Malik and Rajneesh Nath and Faiz Anwer and Cruz, {Jose Carlos} and Myo Htut and Karski, {Erin E.} and Wade Lovelace and Myles Dillon and Eric Butz and Wendy Ying and Arun Balakumaran and Kumar, {Shaji K.}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Nature America, Inc.",

year = "2023",

month = dec,

doi = "10.1038/s41591-023-02306-7",

language = "English (US)",

volume = "29",

pages = "3271",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Publisher Correction

T2 - Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (Nature Medicine, (2023), 29, 2, (422-429), 10.1038/s41591-022-02182-7)

AU - Mailankody, Sham

AU - Matous, Jeffrey V.

AU - Chhabra, Saurabh

AU - Liedtke, Michaela

AU - Sidana, Surbhi

AU - Oluwole, Olalekan O.

AU - Malik, Shahbaz

AU - Nath, Rajneesh

AU - Anwer, Faiz

AU - Cruz, Jose Carlos

AU - Htut, Myo

AU - Karski, Erin E.

AU - Lovelace, Wade

AU - Dillon, Myles

AU - Butz, Eric

AU - Ying, Wendy

AU - Balakumaran, Arun

AU - Kumar, Shaji K.

PY - 2023/12

Y1 - 2023/12

N2 - Correction to: Nature Medicine. Published online 23 January 2023. In the version of this article initially published, the clinical trials registration number was missing from the Abstract and has now been amended in the HTML and PDF versions of the article.

AB - Correction to: Nature Medicine. Published online 23 January 2023. In the version of this article initially published, the clinical trials registration number was missing from the Abstract and has now been amended in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85150197171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150197171&partnerID=8YFLogxK

U2 - 10.1038/s41591-023-02306-7

DO - 10.1038/s41591-023-02306-7

M3 - Comment/debate

C2 - 36932247

AN - SCOPUS:85150197171

SN - 1078-8956

VL - 29

SP - 3271

JO - Nature Medicine

JF - Nature Medicine

IS - 12

ER -

Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (Nature Medicine, (2023), 29, 2, (422-429), 10.1038/s41591-022-02182-7)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this